Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
Status:
Completed
Trial end date:
2019-02-28
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, randomized, placebo-controlled trial involving subjects
with a diagnosis of "definite NASH" with fibrosis (excluding cirrhosis) as determined by the
central histopathologist. Upon successful screening, subjects will be randomized to receive
either emricasan 50 mg BID or emricasan 5 mg BID or matching placebo BID.